Literature DB >> 22177163

Renal function and oncologic outcomes of parenchymal sparing ureteral resection versus radical nephroureterectomy for upper tract urothelial carcinoma.

Jonathan L Silberstein1, Nicholas E Power, Caroline Savage, Tatum V Tarin, Ricardo L Favaretto, Daniel Su, Matthew G Kaag, Harry W Herr, Guido Dalbagni.   

Abstract

PURPOSE: We compared renal function and oncologic outcomes of parenchymal sparing ureteral resection with radical nephroureterectomy for the treatment of upper tract urothelial carcinoma confined to the ureter.
MATERIALS AND METHODS: Review of a large institutional database identified 367 patients treated for primary upper tract urothelial carcinoma with radical nephroureterectomy or parenchymal sparing ureteral resection from 1994 to 2009. Patients with known renal pelvis tumors, muscle invasive urothelial carcinoma, prior cystectomy, contralateral upper tract urothelial carcinoma, metastatic disease or chemotherapy were excluded, leaving 120 patients for analysis. Estimated glomerular filtration rate was calculated using the Modification of Diet in Renal Disease equation. Recurrence-free, cancer specific and overall survival were estimated using Kaplan-Meier analysis.
RESULTS: Radical nephroureterectomy was performed in 87 patients and parenchymal sparing ureteral resection in 33. Median age at surgery was 73 years in the radical nephroureterectomy group (IQR 64-76) vs 70 years (IQR 59-77) in the parenchymal sparing ureteral resection group (p = 0.5). The radical nephroureterectomy and parenchymal sparing ureteral resection cohorts had several disparate clinicopathological variables including preoperative hydronephrosis (80% vs 45%, p = 0.0006), stage (pT3 or greater 26% vs 9%, p = 0.01) and baseline estimated glomerular filtration rate (51 vs 63 ml/minute/1.73 m(2), p = 0.009). Patients who underwent radical nephroureterectomy experienced a significantly greater decrease in estimated glomerular filtration rate after surgery (median -7 vs 0 ml/minute/1.73 m(2), p <0.001). Median followup was 4.2 years. Of the patients 79 experienced cancer recurrence and 44 died (28 of upper tract urothelial carcinoma). There were no obvious differences in the rates of recurrence, cancer specific death or overall death by procedure type. However, due to the limited number of events we cannot exclude the possibility that there are large differences in oncologic outcomes by procedure type.
CONCLUSIONS: Parenchymal sparing ureteral resection is associated with superior postoperative renal function. However, the impact on cancer control cannot be determined conclusively due to the small sample size and putative selection bias.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22177163      PMCID: PMC3689028          DOI: 10.1016/j.juro.2011.09.150

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

1.  Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

Authors:  Atreya Dash; Matthew D Galsky; Andrew J Vickers; Angel M Serio; Theresa M Koppie; Guido Dalbagni; Bernard H Bochner
Journal:  Cancer       Date:  2006-08-01       Impact factor: 6.860

2.  Organ-sparing treatment for ureteral carcinoma?

Authors:  A Leitenberger; A Beyer; J E Altwein
Journal:  Eur Urol       Date:  1996       Impact factor: 20.096

3.  European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update.

Authors:  Morgan Rouprêt; Richard Zigeuner; Juan Palou; Andreas Boehle; Eero Kaasinen; Richard Sylvester; Marko Babjuk; Willem Oosterlinck
Journal:  Eur Urol       Date:  2011-01-14       Impact factor: 20.096

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival.

Authors:  Jan Lehmann; Henrik Suttmann; Iva Kovac; Markus Hack; Jörn Kamradt; Stefan Siemer; Bernd Wullich; Ulrike Zwergel; Michael Stöckle
Journal:  Eur Urol       Date:  2006-11-17       Impact factor: 20.096

6.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

7.  Partial penectomy for patients with squamous cell carcinoma of the penis: the Memorial Sloan-Kettering experience.

Authors:  Ruslan Korets; Theresa M Koppie; Mark E Snyder; Paul Russo
Journal:  Ann Surg Oncol       Date:  2007-09-26       Impact factor: 5.344

8.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

9.  NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network.

Authors:  H Scher; R Bahnson; S Cohen; M Eisenberger; H Herr; J Kozlowski; P Lange; J Montie; A Pollack; D Raghaven; J Richie; W Shipley
Journal:  Oncology (Williston Park)       Date:  1998-07       Impact factor: 2.990

10.  Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients.

Authors:  M C Hall; S Womack; A I Sagalowsky; T Carmody; M D Erickstad; C G Roehrborn
Journal:  Urology       Date:  1998-10       Impact factor: 2.649

View more
  14 in total

1.  Clinical Outcomes in Patients with Panurothelial Carcinoma Treated with Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence.

Authors:  Qiang Li; Melissa Assel; Nicole Benfante; Eugene Pietzak; Aditya Bagrodia; Eugene Cha; Guido Dalbagni; Jonathan Coleman
Journal:  J Urol       Date:  2017-03-22       Impact factor: 7.450

2.  Preoperative hydronephrosis as a predictor of postnephroureterectomy survival in patients with upper tract urothelial carcinoma: a two-center study in Japan.

Authors:  Tomohiro Fukui; Toru Kanno; Go Kobori; Seiji Moroi; Hitoshi Yamada
Journal:  Int J Clin Oncol       Date:  2019-09-03       Impact factor: 3.402

3.  Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma.

Authors:  Jay Simhan; Marc C Smaldone; Brian L Egleston; Daniel Canter; Steven N Sterious; Anthony T Corcoran; Serge Ginzburg; Robert G Uzzo; Alexander Kutikov
Journal:  BJU Int       Date:  2014-04-03       Impact factor: 5.588

4.  Predictive role of preoperative hydronephrosis on poor pathological outcomes and prognosis in upper tract urothelial carcinoma patients: Experience from a nationwide high-volume center in China.

Authors:  Zheng Zhang; Dong Fang; Xiaopeng Chen; Xuesong Li; Gengyan Xiong; Lei Zhang; Qun He; Liqun Zhou
Journal:  Oncol Lett       Date:  2015-08-28       Impact factor: 2.967

Review 5.  Risk-adapted strategy for the kidney-sparing management of upper tract tumours.

Authors:  Thomas Seisen; Pierre Colin; Morgan Rouprêt
Journal:  Nat Rev Urol       Date:  2015-02-24       Impact factor: 14.432

6.  Oncologic outcomes and prognostic impact of urothelial recurrences in patients undergoing segmental and total ureterectomy for upper tract urothelial carcinoma.

Authors:  Jose A Pedrosa; Timothy A Masterson; Kevin R Rice; Hristos Z Kaimakliotis; M Francesca Monn; Richard Bihrle; Michael O Koch; Ronald S Boris
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

Review 7.  A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  D Fang; T Seisen; K Yang; P Liu; X Fan; N Singla; G Xiong; L Zhang; X Li; L Zhou
Journal:  Eur J Surg Oncol       Date:  2016-08-25       Impact factor: 4.424

8.  Treatment strategies for upper tract urothelial carcinoma (UTUC) of a solitary kidney: a single-institutional analysis of 61 cases.

Authors:  Xiaohong Su; Dong Fang; Lei Zhang; Gengyan Xiong; Han Hao; Guangzhi Zhao; Kunlin Yang; Yunchao Xing; Xuesong Li; Liqun Zhou
Journal:  Int Urol Nephrol       Date:  2016-07-04       Impact factor: 2.370

9.  Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer.

Authors:  Shih Ya Hung; Wen Chou Yang; Hao Lun Luo; Chun-Chien Hsu; Yen Ta Chen; Yao Chi Chuang
Journal:  Int Urol Nephrol       Date:  2013-11-08       Impact factor: 2.370

10.  Risk of acute myocardial infarction in upper tract urothelial carcinoma patients receiving radical nephroureterectomy: a population-based cohort study.

Authors:  Shih-Yi Lin; Cheng-Li Lin; Chao-Hsiang Chang; His-Chin Wu; I-Kuan Wang; Che-Yi Chou; Ji-An Liang
Journal:  Oncotarget       Date:  2017-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.